|Bid||0.0000 x 800|
|Ask||0.0000 x 800|
|Day's Range||1.2200 - 1.5000|
|52 Week Range||0.4220 - 28.0499|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 23, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.00|
FORTE BIOSCIENCES, INC. ANNOUNCES ISSUANCE OF NEW U.S. PATENT
Tocagen Inc. (Nasdaq: TOCA), historically a clinical-stage, cancer-selective gene therapy company, announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others, it is changing its special meeting of stockholders related to its previously announced proposed merger with Forte Biosciences, Inc. (the "Special Meeting") to a virtual-only format that will be held via live audio webcast.
Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2019.